Forte Biosciences, Inc. to Review the Second Quarter 2021 Results and Expects to Announce Topline Data From Phase 2 Clinical Trial of FB-401 for the Treatment of Atopic Dermatitis on Sept. 7
| Show full article |
|
This functionality is available for registred users only
|
-
Full nameCbonds Review Magazine
-
Registration countryRussia
-
IndustryOther sectors
-
*** /*** /*** /*** -
М/S&P/F
*** /*** /***









